Cardiac pacemakers

Series
Cardiac electrophysiology
Status
Published
Date
Number of report
050

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for cardiac pacemakers.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

Both single- and dual-chamber pacemakers are considered. Use of pacemakers is considered in complete atrioventricular block and obstructive hypertrophic cardiomyopathy.

Reimbursement analysis covers the following procedures: implantation and replacement of pacemaker.

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of devices for cardiac pacemakers include:

  • Abbott Vascular (Assurity MRI, Endurity MRI)
  • Biotronik (Enitra, Effecta, Epyra, Estella, Evia, Edora)
  • Boston Scientific (Essentio, Accolade, Ingenio, Advantio, Vitalio)
  • Qinming Medical (Qinming)
  • MicroPort CRM (Kora, Reply, Esprit)
  • Medico S.p.A. (Gea, Hera, Eos, Sophos, Helios, Mythos, Easy Plus)
  • Medtronic (Azure, Advisa MRI, Adapta, Micra, Revo MRI SureScan, Sensia, Versa, EnRhythm, EnPulse, Sigma, Kappa)
  • Pacetronix (Tiranga, Pinnacle, CHARAK, Pinnacle-R)
  • Vitatron (Vitatron)

Table of content is not available at the moment. Report is still ongoing.

16

Mar 2023

In January-February 2023, Health Technology Wales published sixteen Medtech-related Topic Exploration Reports (TER), including stereotactic radiosurgery, percutaneous implantation of pulmonary artery pressure sensors, ambulatory patch ECG devices, and others; however, Health Technology Wales will not proceed with full appraisals on these topics. No Guidance was released for Medtech in January-February 2023.

Read more

13

Mar 2023

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 3844 of March 02, 2023, Tuscany Regional Healthcare has published assessments of four medical devices in the cardiovascular and neurovascular treatment areas.

Read more

03

Feb 2023

On January 30, 2023, the Institute for the Hospital Remuneration System (InEK) published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2022. The medical technologies belonging to the cardiovascular, eHealth, gastrointestinal, neuromodulation, neurovascular, peripheral vascular, orthopedic, and other technology groups obtained positive status 1.

Read more

02

Feb 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in January 2023. Twenty-four recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, neurovascular, and orthopedic devices, in-vitro diagnostics, as well as medical aids.

Read more

24

Jan 2023

In December 2022, NHS England launched a consultation on the preliminary 2023/25 NHS Payment Scheme, which is set for two years and will replace the National Tariff Payment System from April 2023. Two new cardiovascular categories (antibacterial envelope, mitral valve repair and replacement devices) are proposed for inclusion in the 2023/24 High Cost Device List (will be updated and reissued for 2024/25). The deadline for comments submission is January 27, 2023.

Read more
(we accept only company emails)